We foresee that every patient should get access to the BOSS™ technology through eye care professionals as early as possible:
>> Young children for screening of refractive disorders and prevention of abnormal vision progression (e.g., keratoconus and high myopia);
>> Individuals in their 20’s to 40’s to get optimal refractive outcomes based on personal localized biomechanical readings;
>> Middle-aged to elderly population to benefit in a variety of surgical procedures in which outcome and healing control are critical.
“I see BOSS™ becoming a standard of care to further optimize laser vision correction, astigmatism correction, and corneal cross-linking as well as to screen patients at risk for developing keratoconus, ectasia, and potentially even high myopia and glaucoma.” Richard L. Lindstrom, MD